CNCE.OQ
Latest Trade
9.02USDChange
0.23(+2.62%)Volume
87,703Today's Range
-
9.1652 Week Range
-
17.80As of on the NASDAQ ∙ Minimum 15 minute delay
Previous Close | 8.79 |
|---|---|
Open | 8.87 |
Volume | 87,703 |
3M AVG Volume | 5.05 |
Today's High | 9.16 |
Today's Low | 8.87 |
52 Week High | 17.80 |
52 Week Low | 5.36 |
Shares Out (MIL) | 23.84 |
Market Cap (MIL) | 209.56 |
Forward P/E | -2.74 |
Dividend (Yield %) | -- |
Concert Pharmaceuticals Q3 Loss Per Share $0.72
Concert Pharma Reports Positive CTP-543 Results From Phase 2 Alopecia Areata Trial
Concert Pharmaceuticals Q2 Loss Per Share $0.78
Concert Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company. The Company is engaged in the discovery and development of small molecule drugs. The Company operates through the development of pharmaceutical products on its own behalf or in collaboration with others. The Company's deuterated chemical entity platform (DCE Platform), has potential across various therapeutic areas. Its product candidates include AVP-786, CTP-656, CTP-730, CTP-543 and JZP-386. The Company's product candidate, CTP-656, is a next generation potentiator that it is initially developing for the treatment of cystic fibrosis in patients having gating mutations, including the G551D mutation. CTP-543 was discovered by applying Concert's deuterium chemistry technology to modify ruxolitinib. AVP-786 is a combination of a dextromethorphan and an ultra-low dose of quinidine. CTP-730 is a phosphodiesterase 4 (PDE4) inhibitor that has potential for the treatment of various inflammatory diseases.
Industry
Biotechnology & Drugs
Executive Leadership
Richard H. Aldrich
Independent Chairman of the Board, Co-Founder
Roger D. Tung
President, Chief Executive Officer, Co-Founder, Director
Marc Becker
Chief Financial Officer, Principal Financial Officer, Principal Accounting Officer
Nancy Stuart
Chief Operating Officer
James V. Cassella
Chief Development Officer
Price To Earnings (TTM) | -- |
|---|---|
Price To Sales (TTM) | 194.58 |
Price To Book (MRQ) | 1.76 |
Price To Cash Flow (TTM) | -- |
Total Debt To Equity (MRQ) | 0.00 |
LT Debt To Equity (MRQ) | 0.00 |
Return on Investment (TTM) | -46.27 |
Return on Equity (TTM) | -43.56 |
* CONCERT PHARMACEUTICALS REPORTS FIRST QUARTER 2018 FINANCIAL RESULTS
* CONCERT PHARMACEUTICALS COMPLETES ENROLLMENT IN PHASE 2A TRIAL OF CTP-543 IN ALOPECIA AREATA
* CONCERT PHARMACEUTICALS INC FILES FOR MIXED SHELF OFFERING OF UP TO $250.0 MILLION - SEC FILING Source text (http://bit.ly/2t6Qumw) Further company coverage: (Reuters.Brief@thomsonreuters.com)
* CONCERT PHARMACEUTICALS REPORTS YEAR ENDED 2017 FINANCIAL RESULTS
* CONCERT PHARMACEUTICALS INC SAYS INTENDS TO COMPLETE PRECLINICAL EVALUATION AND ADVANCE CTP-692 INTO CLINICAL DEVELOPMENT BY YEAR-END 2018 Source text for Eikon: Further company coverage:
* CONCERT PHARMACEUTICALS ANNOUNCES INITIATION OF ENROLLMENT IN SECOND COHORT OF CTP-543 PHASE 2A TRIAL FOR ALOPECIA AREATA
* FDA GRANTS FAST TRACK DESIGNATION TO CONCERT PHARMACEUTICALS’ CTP-543 FOR THE TREATMENT OF ALOPECIA AREATA
* CONCERT PHARMACEUTICALS ANNOUNCES PATENT TRIAL AND APPEAL BOARD DID NOT INSTITUTE PGR PROCEEDING Source text for Eikon: Further company coverage:
* CONCERT PHARMACEUTICALS ANNOUNCES THE APPOINTMENT OF MARC BECKER AS CHIEF FINANCIAL OFFICER
* Concert Pharmaceuticals reports third quarter 2017 financial results and provides company update
* Concert Pharmaceuticals Inc announces completion of enrollment in First Cohort of CTP-543 phase 2a trial
* Concert Pharmaceuticals- on Sept 7, paid total of $30.8 million to hercules capital outstanding under loan and security agreement with Hercules dated June 8
* Concert Pharmaceuticals reports second quarter 2017 financial results and provides company update
* Vertex and Concert Pharmaceuticals complete asset purchase agreement for CTP-656 Source text for Eikon: Further company coverage:
* Concert Pharmaceuticals announces termination of the Hart-Scott-Rodino act waiting period for CTP-656 asset purchase agreement with Vertex
Concert Pharmaceuticals Inc said on Monday the U.S. Food and Drug Administration (FDA) lifted a clinical hold on a trial testing its therapy for alopecia areata, a type of hair loss.
* Fda lifts clinical hold on concert pharmaceuticals clinical trial with ctp-543
Concert Pharmaceuticals Inc said on Monday the U.S. Food and Drug Administration lifted the clinical hold on a mid-stage study testing its drug to treat alopecia areata, a type of hair loss.
* Concert pharmaceuticals announces $30 million venture debt financing from Hercules Capital
* Concert Pharmaceuticals announces departure of chief financial officer, Ryan Daws
Quote and financial data from Refinitiv. Fund performance data provided by Lipper. All quotes delayed a minimum of 15 minutes.